Bristol-Myers Squibb: lung cancer trial stopped early.
(CercleFinance.com) - A pivotal trial of Bristol-Myers Squibb's Opdivo has been stopped early after independent monitors determined that the drug was shown to be effective against non-small cell lung cancer amongst Chinese patients.
The US biopharmaceutical company said the Phase 3 study evaluating Opdivo versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) has been stopped because the independent data monitoring committee concluded that the study met its primary endpoint.
In practice, the drug demonstrated superior overall survival in patients receiving Opdivo compared with the control arm.
The study was conducted on 504 patients, primarily in China, with additional sites in Hong Kong, Russia and Singapore.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The US biopharmaceutical company said the Phase 3 study evaluating Opdivo versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) has been stopped because the independent data monitoring committee concluded that the study met its primary endpoint.
In practice, the drug demonstrated superior overall survival in patients receiving Opdivo compared with the control arm.
The study was conducted on 504 patients, primarily in China, with additional sites in Hong Kong, Russia and Singapore.
Copyright (c) 2017 CercleFinance.com. All rights reserved.